Press Releases, Events

Artemis Therapeutics Announces Issuance Of European Patent For Artemisone For The Treatment Of Viral Infections

NEW YORK, Nov. 28, 2017 /PRNewswire/ — Artemis Therapeutics, Inc. (OTCQB: ATMS), (“Artemis” or the “Company”), a pharmaceutical company developing new therapies to treat life-threatening infectious diseases, today announced the recent issuance by the European Patent Office (EPO) of European Patent No. 2839803 entitled “Methods and Compositions for Treating Viral Infections” covering the Company’s lead product candidate, Artemisone, currently in development for the treatment of malaria and cytomegalovirus (CMV). The European patent will provide intellectual property protection for the Artemisone program in key markets and is expected to expire no earlier than 2033.

“The issuance of this European patent is a significant component of our worldwide intellectual property strategy and augments our existing intellectual property assets such as U.S. patent 9,616,067, ‘Methods and Compositions for Treating Viral Infections’, which was allowed in April of this year,” stated Brian M. Culley, Chief Executive Officer of Artemis. “We believe Artemisone has potential across a broad range of human diseases and the issuance of this patent will provide protection as well as strengthen the commercial opportunities for the development of the program beyond malaria and CMV and into additional viral infectious diseases. We look forward to providing information about those additional indications for Artemisone in the coming months.”

About Artemis Therapeutics

Artemis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of new therapies for the treatment and prevention of severe and life-threatening infectious diseases. The Company’s lead product candidate, Artemisone, is a unique, synthetic artemisinin derivative with potent anti-viral and anti-parasitic properties. The Company currently is evaluating Artemisone for the treatment of p. falciparum malaria and human cytomegalovirus (CMV) infections, including stem cell transplant CMV and congenital CMV. Artemis also plans to evaluate Artemisone for the treatment of additional viral and parasitic diseases. More information is available on the Company’s website: www.artemis-therapeutics.com and Twitter: @ArtemisThera.

Forward Looking Statements:

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: 

Investor Relations
(ir@artemis-therapeutics.com)

SOURCE Artemis Therapeutics, Inc.

Related Links

http://www.artemis-therapeutics.com

Artemis Therapeutics Receives Orphan Drug Designation From U.S. Food And Drug Administration For Artemisone For The Treatment Of Malaria

NEW YORK, Nov. 6, 2017 /PRNewswire/ — Artemis Therapeutics, Inc. (OTCQB: ATMS), (“Artemis” or the “Company”), a pharmaceutical company developing new therapies for the treatment of life-threatening infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for Artemisone, the Company’s lead product candidate, for the treatment of malaria.

“We are delighted Artemisone has received orphan drug designation from the FDA for the treatment of malaria,” stated Brian M. Culley, Chief Executive Officer of Artemis. “With approximately half of the world’s population at risk, malaria presents an unmet global challenge with enormous economic implications. In recent years, artemisinin-resistant malaria has become increasingly common. Our product candidate, Artemisone, is a potent and fast-acting member of the artemisinin class and we believe it may offer a more attractive safety and efficacy profile compared to currently-available artemisinins. We are excited to be moving Artemisone toward additional clinical trials.”

The FDA Orphan Drug designation program provides incentives to sponsors that are developing therapies for rare diseases which affect fewer than 200,000 people in the United States. Artemis is now qualified to receive significant benefits throughout its orphan drug development program including more frequent FDA interactions, protocol assistance, and tax credits for clinical research costs. Also included is a waiver of certain fees and a seven-year term of market exclusivity upon FDA approval of the orphan drug. In 2015, malaria caused 212 million clinical episodes and 429,000 deaths, according to the World Health Organization.

About Artemis Therapeutics

Artemis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of new therapies for the treatment and prevention of severe and life-threatening infectious diseases. The Company’s lead product candidate, Artemisone, is a unique, synthetic artemisinin derivative with potent anti-viral and anti-parasitic properties. The Company currently is evaluating Artemisone for the treatment of p. falciparum malaria and human cytomegalovirus (CMV) infections, including stem cell transplant CMV and congenital CMV. Artemis also plans to evaluate Artemisone for the treatment of additional viral and parasitic diseases. More information is available on the Company’s website: www.artemis-therapeutics.com and Twitter: @ArtemisThera.

Forward Looking Statements:

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

Investor Relations
(ir@artemis-therapeutics.com)

SOURCE Artemis Therapeutics, Inc.

Related Links

http://www.artemis-therapeutics.com

Prof. Dana Wolf, M.D., to Present at CMV2017: 6th International Congenital CMV Conference and 16th International CMV/Betaherpesvirus Workshop

Artemis Therapeutics’ Chief Scientific Officer to participate in Virus and Host Session on Tuesday, May 2, 2017 at 3:15 PM CEST

NEW YORK, NY–(Marketwired – April 27, 2017) – Artemis Therapeutics, Inc. (OTC PINK: ATMS), (“Artemis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of agents for the prevention and treatment of severe and potentially life-threatening infectious diseases, is pleased to announce that Prof. Dana Wolf, M.D., Ted and Frances Chanock Professor of Virology and Head of Clinical Virology at Hadassah Hebrew University Medical Center, and Chief Scientific Officer of Artemis Therapeutics, is an invited speaker at CMV2017: 6th Annual International Congenital CMV Conference and 16th International CMV / Betaherpesvirus Workshop being held April 30-May 4, 2017 at the NH Conference Centre Leeuwenhorst in Noordwijkerhout, Netherlands.

Click to view entire Press Release